相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma
Haley K. Perlow et al.
JOURNAL OF NEURO-ONCOLOGY (2022)
Preferential radiosensitization to glioblastoma cancer stem cell-like cells by a Hsp90 inhibitor, N-vinylpyrrolidone-AUY922
Toshiaki Tani et al.
ONCOLOGY LETTERS (2022)
Radiosensitization and Radioprotection by Curcumin in Glioblastoma and Other Cancers
Vasiliki Zoi et al.
BIOMEDICINES (2022)
Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials
Haley K. Perlow et al.
CANCER (2022)
Emerging therapies for glioblastoma: current state and future directions
Liang Rong et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
Nitroaromatics as hypoxic cell radiosensitizers: A 2D-QSAR approach to explore structural features contributing to radiosensitization effectiveness
Priyanka De et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY REPORTS (2022)
A review of glioblastoma immunotherapy
Ravi Medikonda et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
p53 dynamics vary between tissues and are linked with radiation sensitivity
Jacob Stewart-Ornstein et al.
NATURE COMMUNICATIONS (2021)
The Role of Hypoxia in Glioblastoma Radiotherapy Resistance
Agathe L. Chedeville et al.
CANCERS (2021)
A Review of Newly Diagnosed Glioblastoma
Bryan Oronsky et al.
FRONTIERS IN ONCOLOGY (2021)
Biological Adaptations of Tumor Cells to Radiation Therapy
Angeles Carlos-Reyes et al.
FRONTIERS IN ONCOLOGY (2021)
Curcumin and Radiotherapy Exert Synergistic Anti-Glioma Effect In Vitro
Vasiliki Zoi et al.
BIOMEDICINES (2021)
The Interplay between Glioblastoma and Its Microenvironment
Mark Dapash et al.
CELLS (2021)
MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
Xanthene Miles et al.
FRONTIERS IN ONCOLOGY (2021)
The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression
Guang Lei et al.
CELL RESEARCH (2020)
Small molecule tyrosine kinase inhibitors in glioblastoma
Gayoung Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2020)
Clustered DNA Double-Strand Breaks: Biological Effects and Relevance to Cancer Radiotherapy
Jac A. Nickoloff et al.
GENES (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment
Anaelle A. Dumas et al.
EMBO JOURNAL (2020)
Survival after hypofractionation in glioblastoma: a systematic review and meta-analysis
Jane-Chloe Trone et al.
RADIATION ONCOLOGY (2020)
Purine metabolism regulates DNA repair and therapy resistance in glioblastoma
Weihua Zhou et al.
NATURE COMMUNICATIONS (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Radioresistance in Glioblastoma and the Development of Radiosensitizers
Md Yousuf Ali et al.
CANCERS (2020)
Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress
Yanqiong Zeng et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2020)
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A. Schalper et al.
NATURE MEDICINE (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
Xuejiao Liu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Christopher M. Jackson et al.
NATURE IMMUNOLOGY (2019)
IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma
Satoshi Kofuji et al.
NATURE CELL BIOLOGY (2019)
Curcumin Derivatives Verify the Essentiality of ROS Upregulation in Tumor Suppression
Ikuko Nakamae et al.
MOLECULES (2019)
Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis
Guixiang Liao et al.
FRONTIERS IN ONCOLOGY (2019)
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O'Donnell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Transition metal compounds as cancer radiosensitizers
Martin R. Gill et al.
CHEMICAL SOCIETY REVIEWS (2019)
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02
Evanthia Galanis et al.
NEURO-ONCOLOGY (2018)
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
Prakash Chinnaiyan et al.
NEURO-ONCOLOGY (2018)
CD70, a novel target of CAR T-cell therapy for gliomas
Linchun Jin et al.
NEURO-ONCOLOGY (2018)
The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors
Diana Spiegelberg et al.
CANCER RESEARCH (2018)
Gemcitabine and glioblastoma: challenges and current perspectives
Chiara Bastiancich et al.
DRUG DISCOVERY TODAY (2018)
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)
Kurt G. Pike et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Current state of immunotherapy for glioblastoma
Michael Lim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Cancer Radiosensitizers
Hao Wang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models
Stephen T. Durant et al.
SCIENCE ADVANCES (2018)
Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier
Martina Da Ros et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Hypofractionnated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial.
Damien Pouessel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Using immunotherapy to boost the abscopal effect
Wilfred Ngwa et al.
NATURE REVIEWS CANCER (2018)
Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck
Liam Welsh et al.
BRITISH JOURNAL OF CANCER (2017)
Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy
Ishna N. Mistry et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Purine synthesis promotes maintenance of brain tumor initiating cells in glioma
Xiuxing Wang et al.
NATURE NEUROSCIENCE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The optimism surrounding stereotactic body radiation therapy and immunomodulation
Hannah Tharmalingam et al.
CHINESE CLINICAL ONCOLOGY (2017)
Biological effects of hydrogen peroxide administered intratumorally with or without irradiation in murine tumors
Taiki Takaoka et al.
CANCER SCIENCE (2017)
A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients
Lingjian Yang et al.
CLINICAL CANCER RESEARCH (2017)
Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART)
James P. Flynn et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up
Hugues Duffau
ACTA NEUROCHIRURGICA (2016)
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Maite Verreault et al.
CLINICAL CANCER RESEARCH (2016)
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
Joseph Ciccolini et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wolfgang Wick et al.
CLINICAL CANCER RESEARCH (2016)
RRx-001, A novel dinitroazetidine radiosensitizer
Bryan Oronsky et al.
INVESTIGATIONAL NEW DRUGS (2016)
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
Caroline Happold et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?
Yan Michael Li et al.
JOURNAL OF NEUROSURGERY (2016)
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
Nicholas Brown et al.
PLOS ONE (2016)
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Xiaoman Li et al.
ONCOTARGET (2016)
Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance
Alessia Fidoamore et al.
STEM CELLS INTERNATIONAL (2016)
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma
Andra V. Krauze et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
Sensitization of Glioblastoma Cells to Irradiation by Modulating the Glucose Metabolism
Han Shen et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells
Cristiano Farace et al.
PLOS ONE (2015)
Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: Results of the Accelerated Radiotherapy with Carbogen Breathing and Nicotinamide phase III randomized trial
Saskia E. Rademakers et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2015)
Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase
Ross Carruthers et al.
MOLECULAR ONCOLOGY (2015)
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma
David A. Reardon et al.
NEURO-ONCOLOGY (2015)
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
Daniel J. Ma et al.
NEURO-ONCOLOGY (2015)
Long-term survival after treatment of glioblastoma multiforme with hyperfractionated concomitant boost proton beam therapy
Masashi Mizumoto et al.
PRACTICAL RADIATION ONCOLOGY (2015)
Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5
Jingli Wang et al.
BIOCHEMICAL PHARMACOLOGY (2014)
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
Jenna Kahn et al.
NEURO-ONCOLOGY (2014)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tumor treating fields: a new frontier in cancer therapy
Angela M. Davies et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012 (2013)
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Matthew D. Vesely et al.
RENAISSANCE OF CANCER IMMUNOTHERAPY (2013)
Heterogeneity of tumor-induced gene expression changes in the human metabolic network
Jie Hu et al.
NATURE BIOTECHNOLOGY (2013)
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas
C-H Fan et al.
CELL DEATH & DISEASE (2013)
Potential applications of imaging and image-guided radiotherapy for brain metastases and glioblastoma to mprove patient quality of life
Nam P. Nguyen et al.
FRONTIERS IN ONCOLOGY (2013)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Accelerated Radiotherapy With Carbogen and Nicotinamide for Laryngeal Cancer: Results of a Phase III Randomized Trial
Geert O. Janssens et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A restricted cell population propagates glioblastoma growth after chemotherapy
Jian Chen et al.
NATURE (2012)
PHASE II EVALUATION OF GEFITINIB IN PATIENTS WITH NEWLY DIAGNOSED GRADE 4 ASTROCYTOMA: MAYO/NORTH CENTRAL CANCER TREATMENT GROUP STUDY N0074
Joon H. Uhm et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial
Stephanie E. Combs et al.
BMC CANCER (2010)
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme
Giulio Metro et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas
Shannon E. Fogh et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
David M. Peereboom et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Plasma membrane signaling induced by ionizing radiation
Isabelle Corre et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer
J. Sigmond et al.
ANNALS OF ONCOLOGY (2009)
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
Youjin Lee et al.
BLOOD (2009)
STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect
Sean P. Pitroda et al.
BMC MEDICINE (2009)
Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model
Chun-Xia Wang et al.
BRAIN RESEARCH (2009)
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion
Sarah E. Golding et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Carbogen and nicotinamide in locally advanced bladder cancer: Early results of a phase-III randomized trial
Peter J. Hoskin et al.
RADIOTHERAPY AND ONCOLOGY (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
Postradiation sensitization of the histone deacetylase inhibitor valproic acid
Prakash Chinnaiyan et al.
CLINICAL CANCER RESEARCH (2008)
Chromium-mediated apoptosis: Involvement of DNA-dependent protein kinase (DNA-PK) and differential induction of p53 target genes
Richard Hill et al.
DNA REPAIR (2008)
High-dose single-fraction radiotherapy: Exploiting a new biology?
J. Martin Brown et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Mechanisms of disease: temozolomide and glioblastoma - look to the future
Maciej M. Mrugala et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
Clorinda Schettino et al.
Expert Review of Respiratory Medicine (2008)
Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study
Alessandra Fabi et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Jane E. Visvader et al.
NATURE REVIEWS CANCER (2008)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao et al.
NATURE (2006)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Inhibition of Hsp90 compromises the DNA damage response to radiation
Hideaki Dote et al.
CANCER RESEARCH (2006)
Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms
Arnab Chakravarti et al.
CLINICAL CANCER RESEARCH (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma
MD Prados et al.
NEURO-ONCOLOGY (2006)
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases
JH Suh et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution
SE Combs et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells
RD Rao et al.
NEOPLASIA (2005)
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor
AA Lugade et al.
JOURNAL OF IMMUNOLOGY (2005)
Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study
A Maraveyas et al.
BRITISH JOURNAL OF CANCER (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro
B Pauwels et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats
JW Degen et al.
JOURNAL OF NEUROSURGERY (2003)
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
CJ Bakkenist et al.
NATURE (2003)
The mechanism of action of radios ensitization of conventional chemotherapeutic agents
TS Lawrence et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation
H Machida et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review
N Laperriere et al.
RADIOTHERAPY AND ONCOLOGY (2002)
Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: Results of a phase II New Approaches to Brain Tumor Therapy CNS Consortium safety and efficacy study
L Kleinberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
EGFR overexpression and radiation response in glioblastoma multiforme
FG Barker et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model
PG Guo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme
J Del Rowe et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
